← FDA DRUG APPROVALS

FDA ANDA · ANDA065355

CEFIXIME

Sponsor: LUPIN PHARMS

APPLICATION
ANDA065355
TYPE
ANDA
ORIGINAL APPROVAL
2007-04-10
LATEST ACTION
2016-07-11
ROUTE
ORAL
DOSAGE FORM
FOR SUSPENSION
MARKETING STATUS
Prescription

Products

SUPRAXPrescription
CEFIXIME 200MG/5ML · FOR SUSPENSION · ORAL

Approval history

2016-07-11Labeling · Supplement 20 · standardAP
2013-03-29Labeling · Supplement 18 · standardAP
2007-04-10OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →